Xilio Therapeutics GAAP EPS of -$0.16 misses by $0.06

* Xilio Therapeutics press release [https://seekingalpha.com/pr/20200828-xilio-therapeutics-announces-pipeline-and-business-updates-and-second-quarter-2025-financial] (NASDAQ:XLO [https://seekingalpha.com/symbol/XLO]): Q2 GAAP EPS of -$0.16 misses by $0.06.
* Shares +0.04% PM.
* Collaboration and license revenue was $8.1 million for the quarter ended June 30, 2025, compared to $2.4 million for the quarter ended June 30, 2024.
*
Financial Guidance

Based on its current operating plans, Xilio anticipates that its cash and cash equivalents as of June 30, 2025 will be sufficient to enable it to fund its operating expenses and capital expenditure requirements through the end of the third quarter of 2026.

MORE ON XILIO THERAPEUTICS

* Xilio Therapeutics announces pricing of $50 million public offering [https://seekingalpha.com/news/4454262-xilio-therapeutics-announces-pricing-of-50-million-public-offering]
* Xilio Therapeutics announces public offering; shares down [https://seekingalpha.com/news/4454198-xilio-therapeutics-announces-public-offering-shares-down]
* Seeking Alpha’s Quant Rating on Xilio Therapeutics [https://seekingalpha.com/symbol/XLO/ratings/quant-ratings]
* Historical earnings data for Xilio Therapeutics [https://seekingalpha.com/symbol/XLO/earnings]
* Financial information for Xilio Therapeutics [https://seekingalpha.com/symbol/XLO/income-statement]